Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific releases MADIT-CRT trial results

Boston Scientific releases MADIT-CRT trial results

2nd September 2009

Boston Scientific has revealed the final results of its MADIT-CRT trial into the effect cardiac resynchronisation therapy (CRT) has on the progression of heart failure.

According to the findings, there is significant evidence to prove that this type of treatment does have a positive effect on those suffering from the condition.

During the study, Boston Scientific’s cardiac resynchronisation therapy defibrillators (CRT-Ds) brought about a 34 per cent relative fall in the risk of mortality in patients displaying mild and asymptomatic failure of the heart.

Additionally, CRT-D treatment was found to reduce the relative risk of heart failure events by 41 per cent, compared to the use of implantable cardioverter defibrillator therapy.

Dr Arthur Moss, the principal investigator of the trail, said: “The MADIT-CRT executive committee anticipated that the benefit for the CRT-D therapy group would be dominated by a reduction in heart failure events and the data overwhelmingly confirms that.”

In July, Boston Scientific stated that it is happy to lend its support to the Close the Gap campaign – an initiative designed to highlight discrepancies in the levels of care received by minority groups and women.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.